Taiwan is progressively transitioning into an aging society, leading to escalating challenges regarding elderly health. Diseases such as dementia and Parkinson's disease are becoming increasingly prevalent, significantly affecting patients, their families, and placing substantial strain on the healthcare system. The global Parkinson's disease patient count has exceeded 8.9 million and continues to rise, with over 329,000 deaths reported since 2000, reflecting a more than 100% increase.
In Taiwan, the prevalence of Parkinson's disease has also surged. Data from the National Health Insurance Administration indicate a consistent rise in patients from 2017 to 2021, with female patients increasing notably from around 37,500 in 2017 to approximately 41,000 in 2021, outpacing their male counterparts. These figures underscore the urgent necessity to enhance prevention and treatment strategies for Parkinson's disease, as well as to elevate societal awareness and support for those affected by Parkinson’s disease.
In our project, we designed an innovative plasmid vector that incorporates the ADH and AD6 genes from beetroot, aimed at optimizing L-DOPA synthesis.Through extensive experimental validation and comparison with previous essays, our vector demonstrates significant potential to enhance L-DOPA production compared to other plant-based methods. Our zebrafish experiments revealed that plant-derived L-DOPA exhibits efficacy comparable to, if not superior to, conventional drug formulations.
The L-DOPA we have produced can be formulated and marketed in a manner similar to the existing levodopa/carbidopa medications currently available on the market. Given that levodopa/carbidopa is a well-established treatment for Parkinson's disease, our plant-derived L-DOPA can be developed into tablet and capsule forms, with options for immediate-release and extended-release formulations. They can be packaged in compliance with industry standards, ensuring safety and efficacy for patients. By leveraging the existing distribution channels and regulatory frameworks for Parkinson's disease treatments, our L-DOPA can effectively address the growing demand for this essential medication while providing a sustainable and potentially superior alternative.
1.Modified Bamboo mosaic virus, S strain (BaMV-S)
2.Higher yield compared to other plant-based synthesis
3.Higher bioactivity
While we grow tobacco plants in a controlled greenhouse environment with regulated light and temperature, the growth conditions of the plants can vary from batch to batch. As a result, achieving consistent and optimal yields of L-DOPA is challenging, as not every cultivation cycle can maintain the best production levels. This variability can be influenced by factors such as plant health, nutrient availability, and other environmental conditions, which may lead to fluctuations in the overall output.